MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 571510 | Name: Acetylcysteine
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Acetylcysteine has been used to control irritability and aggressive behaviors in patients with autism and other neuropsychiatric disorders. Acetylcysteine has also been used in the treatment of patients with chronic bronchitis and chronic obstructive pulmonary disease (COPD).

Chemical Structure

Acetylcysteine
Acetylcysteine
CAS#616-91-1

Theoretical Analysis

MedKoo Cat#: 571510

Name: Acetylcysteine

CAS#: 616-91-1

Chemical Formula: C5H9NO3S

Exact Mass: 163.0303

Molecular Weight: 163.19

Elemental Analysis: C, 36.80; H, 5.56; N, 8.58; O, 29.41; S, 19.65

Price and Availability

Size Price Availability Quantity
10g USD 250.00 2 Weeks
25g USD 450.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Acetylcysteine; Parvolex; Mucosil; Ac-Cys-OH; NSC 111180; NSC111180; NSC-111180; NAC; N-acetyl-L-cysteine
IUPAC/Chemical Name
Cysteine, N-acetyl-, L-
InChi Key
PWKSKIMOESPYIA-BYPYZUCNSA-N
InChi Code
InChI=1S/C5H9NO3S/c1-3(7)6-4(2-10)5(8)9/h4,10H,2H2,1H3,(H,6,7)(H,8,9)/t4-/m0/s1
SMILES Code
SC[C@@H](C(O)=O)NC(C)=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Certificate of Analysis
View CoA: current batch, Lot#C21M01C04
Safety Data Sheet (SDS)
View Safety Data Sheet (SDS)
Instruction
View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 163.19 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Hernandez SH, Howland M, Schiano TD, Hoffman RS. The pharmacokinetics and extracorporeal removal of N-acetylcysteine during renal replacement therapies. Clin Toxicol (Phila). 2015;53(10):941-9. doi: 10.3109/15563650.2015.1100305. Epub 2015 Oct 20. PubMed PMID: 26484583. 2: Cazzola M, Calzetta L, Page C, Jardim J, Chuchalin AG, Rogliani P, Matera MG. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-analysis. Eur Respir Rev. 2015 Sep;24(137):451-61. doi: 10.1183/16000617.00002215. Review. PubMed PMID: 26324807. 3: Stutzman D, Dopheide J. Acetylcysteine for treatment of autism spectrum disorder symptoms. Am J Health Syst Pharm. 2015 Nov 15;72(22):1956-9. doi: 10.2146/ajhp150072. PubMed PMID: 26541950. 4: McClure EA, Gipson CD, Malcolm RJ, Kalivas PW, Gray KM. Potential role of N-acetylcysteine in the management of substance use disorders. CNS Drugs. 2014 Feb;28(2):95-106. doi: 10.1007/s40263-014-0142-x. Review. PubMed PMID: 24442756; PubMed Central PMCID: PMC4009342. 5: Racz R, Sweet BV, Sohoni P. Oral acetylcysteine for neuropsychiatric disorders. Am J Health Syst Pharm. 2015 Jun 1;72(11):923-6, 928-9. doi: 10.2146/ajhp140732. Review. PubMed PMID: 25987686. 6: Berk M, Malhi GS, Gray LJ, Dean OM. The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci. 2013 Mar;34(3):167-77. doi: 10.1016/j.tips.2013.01.001. Epub 2013 Jan 29. Review. PubMed PMID: 23369637. 7: Samuni Y, Goldstein S, Dean OM, Berk M. The chemistry and biological activities of N-acetylcysteine. Biochim Biophys Acta. 2013 Aug;1830(8):4117-29. doi: 10.1016/j.bbagen.2013.04.016. Epub 2013 Apr 22. Review. PubMed PMID: 23618697. 8: Heard K, Rumack BH, Green JL, Bucher-Bartelson B, Heard S, Bronstein AC, Dart RC. A single-arm clinical trial of a 48-hour intravenous N-acetylcysteine protocol for treatment of acetaminophen poisoning. Clin Toxicol (Phila). 2014 Jun;52(5):512-8. doi: 10.3109/15563650.2014.902955. Epub 2014 Apr 8. PubMed PMID: 24708414. 9: Fukumoto M. [N-acetylcysteine]. Chudoku Kenkyu. 2013 Jun;26(2):129-33. Review. Japanese. PubMed PMID: 23855246. 10: de Andrade KQ, Moura FA, dos Santos JM, de Araújo OR, de Farias Santos JC, Goulart MO. Oxidative Stress and Inflammation in Hepatic Diseases: Therapeutic Possibilities of N-Acetylcysteine. Int J Mol Sci. 2015 Dec 18;16(12):30269-308. doi: 10.3390/ijms161226225. Review. PubMed PMID: 26694382; PubMed Central PMCID: PMC4691167. 11: Miller JL, Angulo M. An open-label pilot study of N-acetylcysteine for skin-picking in Prader-Willi syndrome. Am J Med Genet A. 2014 Feb;164A(2):421-4. doi: 10.1002/ajmg.a.36306. Epub 2013 Dec 5. PubMed PMID: 24311388. 12: McClure EA, Sonne SC, Winhusen T, Carroll KM, Ghitza UE, McRae-Clark AL, Matthews AG, Sharma G, Van Veldhuisen P, Vandrey RG, Levin FR, Weiss RD, Lindblad R, Allen C, Mooney LJ, Haynes L, Brigham GS, Sparenborg S, Hasson AL, Gray KM. Achieving cannabis cessation -- evaluating N-acetylcysteine treatment (ACCENT): design and implementation of a multi-site, randomized controlled study in the National Institute on Drug Abuse Clinical Trials Network. Contemp Clin Trials. 2014 Nov;39(2):211-23. doi: 10.1016/j.cct.2014.08.011. Epub 2014 Aug 30. PubMed PMID: 25179587; PubMed Central PMCID: PMC4252394. 13: Chiew AL, Isbister GK, Duffull SB, Buckley NA. Evidence for the changing regimens of acetylcysteine. Br J Clin Pharmacol. 2016 Mar;81(3):471-81. doi: 10.1111/bcp.12789. Epub 2015 Nov 23. Review. PubMed PMID: 26387650; PubMed Central PMCID: PMC4767192. 14: Bloch MH, Panza KE, Grant JE, Pittenger C, Leckman JF. N-Acetylcysteine in the treatment of pediatric trichotillomania: a randomized, double-blind, placebo-controlled add-on trial. J Am Acad Child Adolesc Psychiatry. 2013 Mar;52(3):231-40. doi: 10.1016/j.jaac.2012.12.020. PubMed PMID: 23452680; PubMed Central PMCID: PMC3745012. 15: Mlejnek P, Dolezel P. N-acetylcysteine prevents the geldanamycin cytotoxicity by forming geldanamycin-N-acetylcysteine adduct. Chem Biol Interact. 2014 Sep 5;220:248-54. doi: 10.1016/j.cbi.2014.06.025. Epub 2014 Jul 3. PubMed PMID: 24998639. 16: Hildebrandt W, Sauer R, Bonaterra G, Dugi KA, Edler L, Kinscherf R. Oral N-acetylcysteine reduces plasma homocysteine concentrations regardless of lipid or smoking status. Am J Clin Nutr. 2015 Nov;102(5):1014-24. doi: 10.3945/ajcn.114.101964. Epub 2015 Oct 7. PubMed PMID: 26447155. 17: Atabek Yigit E, Ercal N. Release of N-acetylcysteine and N-acetylcysteine amide from contact lenses. Eye Contact Lens. 2013 Sep;39(5):335-40. doi: 10.1097/ICL.0b013e3182a2f8bc. PubMed PMID: 23945523. 18: Sun Z, Fu Q, Cao L, Jin W, Cheng L, Li Z. Intravenous N-acetylcysteine for prevention of contrast-induced nephropathy: a meta-analysis of randomized, controlled trials. PLoS One. 2013;8(1):e55124. doi: 10.1371/journal.pone.0055124. Epub 2013 Jan 30. PubMed PMID: 23383076; PubMed Central PMCID: PMC3559541. 19: Zhou J, Coles LD, Kartha RV, Nash N, Mishra U, Lund TC, Cloyd JC. Intravenous Administration of Stable-Labeled N-Acetylcysteine Demonstrates an Indirect Mechanism for Boosting Glutathione and Improving Redox Status. J Pharm Sci. 2015 Aug;104(8):2619-26. doi: 10.1002/jps.24482. Epub 2015 Jun 5. PubMed PMID: 26052837. 20: Savion N, Izigov N, Morein M, Pri-Chen S, Kotev-Emeth S. S-Allylmercapto-N-acetylcysteine (ASSNAC) protects cultured nerve cells from oxidative stress and attenuates experimental autoimmune encephalomyelitis. Neurosci Lett. 2014 Nov 7;583:108-13. doi: 10.1016/j.neulet.2014.09.034. Epub 2014 Sep 26. PubMed PMID: 25263785.